Leerink Partners analyst Marc Goodman maintained a Buy rating on Biohaven Pharmaceutical Holding Co (NYSE:BHVN) on Monday, setting a price target of $150, which is approximately 23.46% above the present share price of $121.5.
Goodman expects Biohaven Pharmaceutical Holding Co to post earnings per share (EPS) of -$3.23 for the fourth quarter of 2021.
The current consensus among 11 TipRanks analysts is for a Strong Buy rating of shares in Biohaven Pharmaceutical Holding Co, with an average price target of $151.3.
The analysts price targets range from a high of $177 to a low of $111.
In its latest earnings report, released on 06/30/2021, the company reported a quarterly revenue of $92.93 million and a net profit of -$171.89 million. The company's market cap is $7.95 billion.
According to TipRanks.com, Leerink Partners analyst Marc Goodman is currently ranked with 3 stars on a 0-5 stars ranking scale, with an average return of 3.3% and a 47.65% success rate.
Biohaven Pharmaceutical Holding Co. Ltd. is a clinical-stage biopharmaceutical company, which engages in the research and development of late-stage product candidates targeting neurological diseases, including rare disorders. It focuses on a pipeline of product candidates that represent mechanistic platforms, calcitonin gene-related peptide receptor antagonists, and glutamate modulators. The company was founded in September 2013 and is headquartered in New Haven, CT.